Percutaneous Ablation of Metastatic Lymph Nodes: An Insight from the Comparison of Efficacy and Safety Between Cryoablation and Radiofrequency Ablation.
Computed tomography
Cryoablation
Lymph nodes
Radiofrequency ablation
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
08
02
2022
accepted:
26
05
2022
pubmed:
11
6
2022
medline:
27
7
2022
entrez:
10
6
2022
Statut:
ppublish
Résumé
To retrospectively compare efficacy and safety of computed tomography (CT)-guided percutaneous ablation of metastatic lymph nodes (LN) between cryoablation (CA) and radiofrequency ablation (RFA). A bi-central institutional database research identified 28 patients (42 metastatic LNs) who underwent percutaneous CT-guided ablation. RFA group included 18 patients/26 tumors; CA group included 10 patients/16 tumors. Contrast-enhanced CT or MRI was used for post-ablation follow-up. Patient and tumor characteristics, technical and clinical success on a per tumor and a per patient basis and complication rates were recorded, evaluated and compared between the 2 groups. Both RFA and CA groups had the same median tumor size (2.00 vs. 2.20 cm, p = 0.257), the same median follow-up time (20.50 vs. 20.00 months, p = 0.923) and the same median length of hospital stay (1.00 vs. 1.00 days, p = 0.283). CA group had a higher median procedure time (110.50 vs. 52.00 min, p = 0.001). On a per lesion basis, the overall complete response post-ablation was 88.46% (23/26 lesions) in the RFA and 93.75% (15/16 lesions) in the CA group; no association was revealed between local tumor control and ablation technique (p = 0.709). No complications were recorded in both Groups. On a per patient basis, CA had a longer disease-free interval (24.00 vs. 14.50, p = 0.012) which, however, did not affect the overall survival between the two techniques (26.0 vs. 22.0, p = 0.099 for CA and RFA respectively). Our limited data suggest that CT-guided RFA and CA are equally effective on terms of efficacy and safety for the treatment of metastatic lymph nodes.
Identifiants
pubmed: 35680674
doi: 10.1007/s00270-022-03191-2
pii: 10.1007/s00270-022-03191-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1134-1140Informations de copyright
© 2022. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Références
Obinu A, Gavini E, Rassu G, Maestri M, Bonferoni MC, Giunchedi P. Lymph node metastases: importance of detection and treatment strategies. Expert Opin Drug Deliv. 2018;15(5):459–67.
doi: 10.1080/17425247.2018.1446937
Huang F, Wu G, Yang K. Oligometastasis and oligo-recurrence: more than a mirage. Radiat Oncol. 2014;9:1–9.
doi: 10.1186/s13014-014-0230-6
Filippiadis D, Charalampopoulos G, Tsochatzis A, Reppas L, Mazioti A, Kelekis A, Kelekis N. Feasibility and safety of percutaneous computed tomography guided radiofrequency ablation of lymph nodes in oligometastatic patients: a single center’s experience. Br J Radiol. 2021;94(1121):20200445.
doi: 10.1259/bjr.20200445
Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH, et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis. Radiology. 2017;282(1):259–70.
doi: 10.1148/radiol.2016151807
Tsoumakidou G, Mandralis K, Hocquelet A, Duran R, Denys A. Salvage lymph-node percutaneous cryoablation: safety profile and oncologic outcomes. Cardiovasc Intervent Radiol. 2020;43(2):264–72.
doi: 10.1007/s00270-019-02341-3
Qiu Y, Xing Z, He Y, Liu J, Yang Q, Luo Y. Ultrasound-guided thermal ablation for cervical lymph node metastasis from thyroid carcinoma: a meta-analysis of clinical efficacy and safety. Lasers Med Sci. 2021;37(3):1747–54. https://doi.org/10.1007/s10103-021-03428-5 .
doi: 10.1007/s10103-021-03428-5
pubmed: 34617202
Autrusseau PA, Cazzato RL, Koch G, Ramamurthy N, Auloge P, De Marini P, Lipsker D, Gangi A, Garnon J. Freezing nodal disease: local control following percutaneous image-guided cryoablation of locoregional and distant lymph node oligometastases: a 10-year, single-center experience. J Vasc Interv Radiol. 2021;32(10):1435–44.
doi: 10.1016/j.jvir.2021.07.002
Frich PS, Sigstad E, Berstad AE, Fagerlid KH, Paulsen TH, Bjøro T, Flinder LI. Long-term efficacy of ethanol ablation as treatment of metastatic lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab. 2022;107(5):e2141–7.
doi: 10.1210/clinem/dgab907
Cornelis FH, Monard E, Moulin MA, Vignaud E, Laveissiere F, Ben Ammar M, et al. Sedation and analgesia in interventional radiology: Where do we stand, where are we heading and why does it matter? Diagn Interv Imaging. 2019;100:753–62.
doi: 10.1016/j.diii.2019.10.002
Cazzato RL, Garnon J, Ramamurthy N, et al. Percutaneous image-guided cryoablation: current applications and results in the oncologic field. Med Oncol. 2016;33:1–16.
doi: 10.1007/s12032-016-0848-3
Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306.
doi: 10.1016/j.jhep.2019.09.026
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. CIRSE quality assurance document and standards for classification of complications: the CIRSE classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141–6.
doi: 10.1007/s00270-017-1703-4
Puijk RS, Ahmed M, Adam A, et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology. 2021;301(3):533–40.
doi: 10.1148/radiol.2021203715
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.
doi: 10.1200/JCO.1995.13.1.8
Mu L, Sun L, Pan T, Lyu N, Li S, Li X, et al. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperth. 2018;34(1):59–67.
doi: 10.1080/02656736.2017.1318332
Yuan Z, Xing A, Zheng J, Li W. Safety and technical feasibility of percutaneous ablation for lymph node metastases of hepatocellular carcinoma. Int J Hyperth. 2019;36(1):160–8.
doi: 10.1080/02656736.2018.1542510
Kodama T, Matsuki D, Tada A, Takeda K, Mori S. New concept for the prevention and treatment of metastatic lymph nodes using chemotherapy administered via the lymphatic network. Sci Rep. 2016;6:32506.
doi: 10.1038/srep32506
Karnes RJ, Murphy CR, Bergstralh EJ, et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11Ccholine positron emission tomography/computerized tomography. J Urol. 2015;193(1):111–6.
doi: 10.1016/j.juro.2014.08.082